Closed
Exercise
Calculated transaction value
$0

Ragosa Mark Chief Financial Officer

Transaction date Nov 2, 2026
Public filing date Nov 3, 2026
Filing lag Filed 1 day later

KNSA daily price context

Close on/before transaction
$90.8 Nov 2, 2026
First close after public filing
-- Unavailable
30-day return after filing
-- Through Unavailable

Source details

Reported owner
Not disclosed
Source asset code
Derivative
Security
Share Option on Class A Ordinary Share
Quantity / price
9,636 shares @ $0
SEC ownership
Direct
Transaction code
M
Form
4
Filing identifier
0001835458-26-000014
Filing cohort

Transactions in this filing

Showing 12 of 12
Trades
12
Issuers
1
Estimated value
$3.87M
Buys / sales
0 / 4
Transactions reported in the same official filing
Issuer Transaction Traded Value
Kiniksa Pharmaceuticals International, Plc KNSA Exercise Nov 2, 2026 $103.68K
Kiniksa Pharmaceuticals International, Plc KNSA Current Exercise Nov 2, 2026 $0
Kiniksa Pharmaceuticals International, Plc KNSA Exercise Nov 2, 2026 $59.81K
Kiniksa Pharmaceuticals International, Plc KNSA Exercise Nov 2, 2026 $145.11K
Kiniksa Pharmaceuticals International, Plc KNSA Exercise Nov 2, 2026 $171.14K
Kiniksa Pharmaceuticals International, Plc KNSA Sale Nov 2, 2026 $1.28M
Kiniksa Pharmaceuticals International, Plc KNSA Sale Nov 2, 2026 $1.12M
Kiniksa Pharmaceuticals International, Plc KNSA Exercise Nov 2, 2026 $0
Kiniksa Pharmaceuticals International, Plc KNSA Exercise Nov 2, 2026 $0
Kiniksa Pharmaceuticals International, Plc KNSA Sale Nov 2, 2026 $966.5K
Kiniksa Pharmaceuticals International, Plc KNSA Sale Nov 2, 2026 $20.68K
Kiniksa Pharmaceuticals International, Plc KNSA Exercise Nov 2, 2026 $0